PFE
PFIZER INCPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 3 to Feb 10 ▲ 2 buys: Susan Collins, Gilbert Cisneros bought, last disclosed Mar 26
- Jun 9 ▼ 1 insider sell $51.4K at $25.70
- Jul 6 ▼ HSBC downgrades
- Jul 24 to Jul 31 4 court rulings: Steele v. Pfizer Inc et al; Pfizer Inc. v. Sanofi Pasteur Inc. and 2 more
- Aug 5 to Aug 12 ▲ 2 days of insider buys: $3.0M by 3 insiders, avg $25.77
- Aug 5 ▼ 1 insider sell $83.3K at $25.40
- Sep 11 to Oct 7 ▲ 3 buys: Ro Khanna bought, last disclosed Nov 9
- Oct 12 Trial readout: Results Pending: PF-07868489 (Phase 2), Completed 73d ago
- Oct 24 Trial readout: Results Pending: RSVpreF (Phase 3), Completed 60d ago
- Oct 30 NIETO v. PFIZER, INC. et al
- Nov 2 Trial readout: Results Pending: MET233 and MET097 (Phase 2), completed 34…
- Nov 3 ▲ Pfizer reported Q3 2026 adjusted diluted EPS of $0.87, beating the $…
Signal stack
Where each data set points today.
- InsidersBULLISH
3 insiders bought $3.0M at an average $25.77. 1 insider sold $134.7K. Price is 12% above their cost.
- InstitutionsMIXED
Q2 2026: 47 added (2 new), 36 trimmed or exited. Largest new: Tudor Investment Et Al $16.8M.
- AnalystsMIXED
13 of 34 rate it Buy or better. Median target $30.00 (+4%).
- Short sellersSTEADY
Short interest −2.5% to 134.42M shares. 4.6 days to cover, ≈2.4% of shares.
- TrendUPTREND
0% above its 50-day average.
- SocialQUIET
Crowd 53° (neutral) this week from 16 mentions: 2 bullish, 1 bearish. No setup is alerting. Excludes 1 subscriber-only day.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| WELLINGTON MANAGEMENT GROUP LLP | TRIM | $670.1M |
| CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | ADD | $415.7M |
| AMERIPRISE FINANCIAL INC | TRIM | $345.9M |
| Assenagon Asset Management S.A. | ADD | $286.6M |
| VICTORY CAPITAL MANAGEMENT INC | TRIM | $220.4M |
| PRUDENTIAL FINANCIAL INC | ADD | $185.9M |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | DOUBLED | $157.7M |
| D. E. Shaw & Co., Inc. | TRIM | $130.4M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
34 analystsPrice is inside the target range. Median implies +4%.Targets as of Nov 16, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 6, 2026 | Freedom Broker MAINTAIN | Buy |
| Nov 5, 2026 | Guggenheim MAINTAIN | Buy |
| Nov 4, 2026 | UBS MAINTAIN | Neutral |
| Nov 4, 2026 | Scotiabank MAINTAIN | Sector Outperform |
| Nov 4, 2026 | Citigroup MAINTAIN | Neutral |
| Nov 4, 2026 | RBC Capital MAINTAIN | Sector Perform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
BOURLA ALBERT Chairman & CEO Oct 30, 2026 | AWARD | $610.40 |
BOURLA ALBERT Chairman & CEO Oct 15, 2026 | AWARD | $588.80 |
BOURLA ALBERT Chairman & CEO Oct 13, 2026 | AWARD | $2.0K |
BOURLA ALBERT Chairman & CEO Sep 30, 2026 | AWARD | $598.92 |
SMITH JAMES C Director Sep 25, 2026 | AWARD | $45.0K |
Taraporevala Cyrus Director Sep 25, 2026 | AWARD | $37.5K |
NARAYEN SHANTANU Director Sep 25, 2026 | AWARD | $50.0K |
Quincey James Director Sep 25, 2026 | AWARD | $38.7K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
21 filings · 7 bullish · 2 bearish · 1 mixed · 11 neutral- NEUTRAL 8-KNov 3, 2026
Pfizer announced the permanent appointment of Cecile Guegan as CFO and Executive Vice President…
Monitor Pfizer's upcoming quarterly earnings for any changes in financial strategy or capital allocation under the permanent CFO. No immediate trading catalyst from this appointment.
- BULLISH 8-KNov 3, 2026
Pfizer reported Q3 2026 adjusted diluted EPS of $0.87, beating the $0.73 consensus by 19.2%, on…
The guidance raise and strong beat on both EPS and revenue suggest accelerating momentum in the core non-COVID portfolio. Watch for continued execution on the cost realignment program and pipeline…
- NEUTRAL COURT-RULINGOct 30, 2026
The District of New Jersey granted Pfizer's motions to dismiss a former employee's retaliation and…
The dismissal is procedural and without prejudice; monitor whether plaintiff files an amended complaint within 30 days. If no amendment is filed or the next complaint is similarly dismissed with…
- MIXED INST-CLUSTEROct 23, 2026
Five asset managers added $50.3M in PFE positions during Q3 2026, while two large holders trimmed…
The cluster shows a split: two large holders (Artemis, Assenagon) significantly reduced exposure, while five smaller managers added. The net selling is notable but the breadth of buyers suggests the…
All PFE filing & press-release reports (21)
- 8-K reportNov 3, 2026
- 8-K reportNov 3, 2026
- COURT-RULING reportOct 30, 2026
- INST-CLUSTER reportOct 23, 2026
- INSIDER-BUY reportAug 12, 2026
- COURT-RULING reportAug 13, 2026
- CLUSTER reportAug 12, 2026
- CLUSTER reportAug 6, 2026
- CLUSTER reportAug 5, 2026
- INSIDER-BUY reportAug 5, 2026
- 8-K reportAug 4, 2026
- COURT-RULING reportJul 31, 2026
- COURT-RULING reportJul 24, 2026
- HSBC downgrades PFE to Hold, PT $28 (-12.5%)Jul 6, 2026
- 8-K reportJun 18, 2026
- 8-K reportJun 18, 2026
- COURT-RULING reportJun 16, 2026
- RBC Capital upgrades PFE to Sector Perform, PT $25 (-2.7%)Jun 10, 2026
- 8-K reportMay 5, 2026
- CICC initiates PFE at Outperform with $33 PT, +15.6% upside vs. consensus meanApr 16, 2026
- DEFA14A reportMar 12, 2026